drugset / Trial / NCT06126575
A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function
Non-randomizedParallel-groupOpen-labelOther
Summary
This is a Phase 1, multi-center, open-label, non-randomized, parallel group study to evaluate the effect of severe hepatic impairment on the PK, safety and tolerability of a single oral dose of Elacestrant.
Timeline
- Start
- 2023-03-13
- Primary completion
- 2024-11-11
- Completion
- 2024-11-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elacestrant | Other / unclassified | 200 mg | Oral |
Indications
No indication recorded.